NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MTSR

Metsera Inc

Jun 30 • 04:00PM ET

28.45

Dollar change -0.14
Percentage change -0.49	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VB XBI VXF VBR VBK IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	51.74%	Shs Outstand	104.87M	Perf Week	-1.90%
Market Cap	2.99B	Forward P/E	-	EPS next Y	-3.50	Insider Trans	10.66%	Shs Float	50.70M	Perf Month	3.12%
Enterprise Value	2.41B	PEG	-	EPS next Q	-0.64	Inst Own	38.75%	Short Float	17.41%	Perf Quarter	1.61%
Income	-	P/S	-	EPS this Y	77.77%	Inst Trans	85.41%	Short Ratio	8.20	Perf Half Y	-
Sales	-	P/B	5.90	EPS next Y	-8.62%	ROA	-	Short Interest	8.83M	Perf YTD	7.36%
Book/sh	4.82	P/C	5.08	EPS next 5Y	32.63%	ROE	-	52W High	37.99 -25.10%	Perf Year	-
Cash/sh	5.60	P/FCF	-	EPS past 3/5Y	-1497.55% -	ROIC	-	52W Low	12.30 131.30%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.62% 10.72%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.55	EPS Q/Q	-	SMA20	-2.73%	Beta	-	Target Price	55.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	7.10%	Rel Volume	0.50	Prev Close	28.59
Employees	81	LT Debt/Eq	0.00	Earnings	May 12 BMO	SMA200	8.48%	Avg Volume	1.08M	Price	28.45
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.99% -	Trades		Volume	540,006	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-25	Initiated	Wells Fargo	Overweight	$65
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Jun-24-25 09:55AM	Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)
Jun-11-25 07:56PM	Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results (Insider Monkey) -5.81%
Jun-10-25 07:00AM	Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +15.50%
Jun-09-25 04:08PM	Obesity Newcomer Metsera Enters The Ring With A Punch And A Big Stock Jump (Investor's Business Daily) +10.55%
09:48AM	Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch (Investor's Business Daily)
08:06AM	Loading…
08:06AM	Metsera shares climb on early data for amylin-targeting obesity shot (BioPharma Dive)
07:00AM	Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i (GlobeNewswire)
Jun-05-25 07:30AM	Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-12-25 07:00AM	Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) +10.52%
May-08-25 04:01PM	Metsera to Present at Bank of America 2025 Global Healthcare Conference (GlobeNewswire) +7.00%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-26-25 07:00AM	Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress (GlobeNewswire)
Mar-15-25 04:42PM	Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:13AM	Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Mar-03-25 02:50PM	Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey) +15.01%
05:02AM	Loading…
Mar-01-25 05:02AM	Q4 2024 Amneal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Metsera to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 02:04PM	Wall Street bullish on Metsera following January IPO on obesity drug pipeline (Investing.com) -8.32%
Feb-19-25 02:50PM	Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTSR

Metsera Inc

Upgrade your FINVIZ experience